NDA 214377 · Msd
Verquvo
Vericiguat · Oral · Soluble Guanylate Cyclase Stimulator
NovelPriority reviewCDER novel approval, Jan 19, 2021: To mitigate the risk of cardiovascular death and hospitalization for chronic heart failure
Last checked: Nov 20, 2026Latest source record: Jan 21, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Jan 19, 2021
Approved uses
2
Original approval plus efficacy supplements
Registered trials
37
3 Phase 3, 11 recruiting
FAERS reports
994
510 serious, 152 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: EMBRYO-FETAL TOXICITY Females of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment. Do not administer VERQUVO to a pregnant female because it may cause fetal harm [see Dosage and Administration (2.2) , Warnings and Precautions (5.1) , and Use in Specific Populations (8.3) ] . WARNING: EMBRYO-FETAL TOXICITY See full prescribing information for complete boxed warning. Do not administer VERQUVO to a pregnant female because it may cause fetal harm. ( 4 , 5.1 , 8.1 ) Females of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment....
What it is approved for
From the label in effect Jan 21, 2026.
VERQUVO ® is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45% [see Clinical Studies (14) ] . VERQUVO is a soluble guanylate cyclase (sGC) stimulator, indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%. ( 1 )
Mechanism: Vericiguat is a stimulator of soluble guanylate cyclase (sGC), an important enzyme in the nitric oxide (NO) signaling pathway. When NO binds to sGC, the enzyme catalyzes the synthesis of intracellular cyclic guanosine monophosphate (cGMP), a second messenger that plays a role in the regulation of vascular tone, cardiac contractility, and cardiac remodeling. Heart failure is associated with impaired synthesis of NO and decreased activity of sGC, which may contribute to myocardial and vascular dysfunction. By directly stimulating sGC, independently of and synergistically with NO, vericiguat...
Therapeutic areas: Cardiovascular and metabolic · Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 21, 2026 Supplement 5 · Efficacy LabelLetter
- Jan 19, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
3 products under this application
- VERQUVO · VERICIGUAT 5MG · TABLET, ORAL · Prescription
- VERQUVO · VERICIGUAT 10MG · TABLET, ORAL · Prescription
- VERQUVO · VERICIGUAT 2.5MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Vericiguat" as an intervention, any sponsor and status, largest first.
- A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05093933 · 6,106 participants · Start Nov 2, 2021 · Primary completion Nov 20, 2024
Drug: Vericiguat; Placebo · For: Chronic Heart Failure With Reduced Ejection Fraction
Sites: Alexander City, Alabama; Birmingham, Alabama; Huntsville, Alabama · 519 sites in all
- A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02861534 · 5,050 participants · Start Sep 20, 2016 · Primary completion Jun 18, 2019
Drug: Vericiguat; Placebo for vericiguat · For: Heart Failure; Chronic Heart Failure With Reduced Ejection Fraction
- Patient-reported Outcomes in Vericiguat-treated Patients With HFpEFPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT03547583 · 789 participants · Start Jun 15, 2018 · Primary completion Oct 15, 2019
Drug: Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets; Placebo · For: Chronic Heart Failure With Preserved Ejection Fraction
Sites: Beverly Hills, California; Carmichael, California; West Hills, California · 177 sites in all
- Perioperative Vericiguat in Patients Undergoing Cardiovascular SurgeryPivotal-lookingNot yet recruiting
Nanjing Medical UniversityAcademic, hospital or other
NCT07594509 · 600 participants (planned) · Start May 31, 2026 · Primary completion Dec 31, 2028
Drug: Vericiguat; Standard of Care Group · For: Cardio Vascular Disease; Cardiopulmonary Bypass
Sites: Nanjing, China
- Comparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Heart Failure PatientsPivotal-lookingNot yet recruiting
National Institute of Cardiovascular Diseases, PakistanAcademic, hospital or other
NCT07697833 · 500 participants (planned) · Start Jul 15, 2026 · Primary completion May 15, 2027
Drug: Vericiguat tablet; Placebo · For: Heart Failure With Reduced Ejection Fraction (HFrEF)
- Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)Pivotal-lookingCompleted
BayerBayer (BAYRY)
NCT01951638 · 477 participants · Start Nov 6, 2013 · Primary completion Aug 18, 2015
Drug: Vericiguat (BAY1021189) (1.25 mg); Vericiguat (BAY1021189) (5 mg) and 1 more · For: Heart Failure
Sites: Fountain Valley, California; Fort Lauderdale, Florida; Naples, Florida · 158 sites in all
- Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)Pivotal-lookingCompleted
BayerBayer (BAYRY)
NCT01951625 · 456 participants · Start Nov 29, 2013 · Primary completion May 14, 2015
Drug: Vericiguat (BAY1021189) (1.25 mg); Vericiguat (BAY1021189) (5 mg) and 1 more · For: Heart Failure
Sites: Fountain Valley, California; Wilmington, Delaware; Fort Lauderdale, Florida · 157 sites in all
- Micro-axial Flow Pump-Supported PCI in Complex Coronary Artery Disease With Ischemic LV DysfunctionPivotal-lookingNot yet recruiting
China National Center for Cardiovascular DiseasesGovernment (non-federal)
NCT07678021 · 452 participants (planned) · Start Aug 1, 2026 · Primary completion Dec 31, 2029
Drug: Optimal medical therapy (OMT) · For: Coronary Artery Disease (CAD)
Sites: Beijing, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hypotension116
- death98
- cardiac failure77
- dizziness69
- product dose omission issue55
- no adverse event49
- blood pressure decreased43
- anaemia40
- fatigue37
- dyspnoea36
- malaise34
- nausea31
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 2 |
| 2018 | 3 |
| 2021 | 114 |
| 2022 | 218 |
| 2023 | 213 |
| 2024 | 177 |
| 2025 | 181 |
| 2026 | 86 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Verquvo (Vericiguat)
2024 spending
$49.7M
Beneficiaries
11,127
49,590 claims
Per beneficiary
$4,465
$21.88 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $3,048,794 |
| 2022 | $15,714,170 |
| 2023 | $34,422,269 |
| 2024 | $49,680,167 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
Armstrong PW, Pieske B, Anstrom KJ, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Multicenter Study
- A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction.
Tromp J, Ouwerkerk W, van Veldhuisen DJ, et al. · JACC Heart Fail 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Pharmacologic Treatment of Heart Failure With Reduced Ejection Fraction: An Updated Systematic Review and Network Meta-Analysis.
van Essen BJ, Ceelen DCH, Ouwerkerk W, et al. · J Am Coll Cardiol 2025 · Systematic Review, Network Meta-Analysis
- Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial.
Butler J, McMullan CJ, Anstrom KJ, et al. · Lancet 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Comparative efficacy of vericiguat to sacubitril/valsartan for patients with heart failure reduced ejection fraction: Systematic review and network meta-analysis.
Kang DW, Kang SH, Lee K, et al. · Int J Cardiol 2024 · Systematic Review, Comparative Study
- Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial.
Butler J, Fioretti F, McMullan CJ, et al. · Eur Heart J 2026 · Randomized Controlled Trial, Multicenter Study
Sponsor: Merck & Co.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.